Celia Hart

General Partner

CELIA HAS MORE THAN 15 YEARS’ EXPERIENCE IN PRIVATE EQUITY. SHE JOINED THE TEAM IN 2005 AND IS RESPONSIBLE FOR THE EARLY TEAM, THE HEALTHCARE SECTOR AND THE SUPERNOVA 2 FUND.

Before joining Supernova Invest, Celia held several high-level positions at Cambridge Antibody Technology (Medimmune since its acquisition by AstraZeneca), one of the stars of UK biotech.

She played a role in developing a number of therapeutic antibodies, including some in co-development with international industrial partners. Celia holds a master’s degree in chemistry from the University of Geneva (Switzerland), a PhD from the University of Oxford, and an MBA from Grenoble École de Management (France).

Celia is a member of the board of directors or supervisory board of several companies, including Algaia, Bioaxial, Carthera, Diabeloop, Enobraq, Keranova, LX Repair, NH Theraguix, Uromems, M2Care and Acusurgical.

celia.hart@supernovainvest.com

Paris 75001

9 rue Duphot

Grenoble 38000

3 Parvis Louis Néel –
Minatec

Contact-us

+33 (0)1 86 64 01 85
contact@supernovainvest.com

©2021 Supernova Invest

All rights reserved
Legal
Privacy policy